{"transactions":[{"id":718231,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T22:24:22.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":15528,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date."}],"balance_after":15528,"derivative":{"exercise_price":28.14,"expiration_date":"2036-06-29","underlying":"Common Stock","underlying_shares":15528},"source":{"system":"sec-edgar","filing":"0001311210-26-000006","document":"form4-07022026_100719.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000131121026000006/form4-07022026_100719.xml","form_type":"4"}},{"id":718230,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T22:24:22.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":3553,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (\"RSU\") grant.  The shares underlying this RSU vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date."}],"balance_after":3553,"source":{"system":"sec-edgar","filing":"0001311210-26-000006","document":"form4-07022026_100719.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000131121026000006/form4-07022026_100719.xml","form_type":"4"}},{"id":739902,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T20:28:25.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":16900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control."}],"balance_after":16900,"derivative":{"exercise_price":23.3,"expiration_date":"2036-06-10","underlying":"Stock Option (Rights to Buy)","underlying_shares":16900},"source":{"system":"sec-edgar","filing":"0001311210-26-000003","document":"wk-form4_1781296101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000131121026000003/wk-form4_1781296101.xml","form_type":"4"}},{"id":739901,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T20:28:25.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":5700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control."}],"balance_after":44300,"source":{"system":"sec-edgar","filing":"0001311210-26-000003","document":"wk-form4_1781296101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000131121026000003/wk-form4_1781296101.xml","form_type":"4"}},{"id":751208,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-06-04T01:04:45.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":1593,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."}],"balance_after":1593,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":1593},"source":{"system":"sec-edgar","filing":"0001193125-26-256125","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000119312526256125/ownership.xml","form_type":"4"}},{"id":751207,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-06-04T01:04:45.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":10507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders."}],"balance_after":10507,"derivative":{"exercise_price":53.46,"expiration_date":"2036-06-02","underlying":"Common Shares","underlying_shares":10507},"source":{"system":"sec-edgar","filing":"0001193125-26-256125","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000119312526256125/ownership.xml","form_type":"4"}},{"id":751206,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-06-04T01:04:45.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":false,"shares":2645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":2645},"source":{"system":"sec-edgar","filing":"0001193125-26-256125","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000119312526256125/ownership.xml","form_type":"4"}},{"id":751205,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-04T01:04:45.000Z","date":"2026-06-01","kind":"exercise","planned":false,"acquired":true,"shares":2645,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Common Shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":2645,"source":{"system":"sec-edgar","filing":"0001193125-26-256125","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000119312526256125/ownership.xml","form_type":"4"}},{"id":974246,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:22:38.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13590,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a \"Cash-Out Stock Option\") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":2.32,"underlying":"Common Stock","underlying_shares":13590},"source":{"system":"sec-edgar","filing":"0001311210-25-000004","document":"form4-12102025_061234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000131121025000004/form4-12102025_061234.xml","form_type":"4"}},{"id":974245,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:22:38.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13820,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":7.32,"underlying":"Common Stock","underlying_shares":13820},"source":{"system":"sec-edgar","filing":"0001311210-25-000004","document":"form4-12102025_061234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000131121025000004/form4-12102025_061234.xml","form_type":"4"}},{"id":974244,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:22:38.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":15.6,"underlying":"Common Stock","underlying_shares":5250},"source":{"system":"sec-edgar","filing":"0001311210-25-000004","document":"form4-12102025_061234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000131121025000004/form4-12102025_061234.xml","form_type":"4"}},{"id":974243,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:22:38.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":9.9,"underlying":"Common Stock","underlying_shares":5250},"source":{"system":"sec-edgar","filing":"0001311210-25-000004","document":"form4-12102025_061234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000131121025000004/form4-12102025_061234.xml","form_type":"4"}},{"id":974242,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:22:38.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":37,"underlying":"Common Stock","underlying_shares":5250},"source":{"system":"sec-edgar","filing":"0001311210-25-000004","document":"form4-12102025_061234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000131121025000004/form4-12102025_061234.xml","form_type":"4"}},{"id":974241,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:22:38.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":256.4,"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001311210-25-000004","document":"form4-12102025_061234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000131121025000004/form4-12102025_061234.xml","form_type":"4"}},{"id":974240,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:22:38.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":115.2,"underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001311210-25-000004","document":"form4-12102025_061234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000131121025000004/form4-12102025_061234.xml","form_type":"4"}},{"id":974239,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:22:38.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":134.1,"underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001311210-25-000004","document":"form4-12102025_061234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000131121025000004/form4-12102025_061234.xml","form_type":"4"}},{"id":974238,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:22:38.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":62.5,"underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001311210-25-000004","document":"form4-12102025_061234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000131121025000004/form4-12102025_061234.xml","form_type":"4"}},{"id":974237,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:22:38.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3360,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":27.5,"underlying":"Common Stock","underlying_shares":3360},"source":{"system":"sec-edgar","filing":"0001311210-25-000004","document":"form4-12102025_061234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000131121025000004/form4-12102025_061234.xml","form_type":"4"}},{"id":974236,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:22:38.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6476,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":27.5,"underlying":"Common Stock","underlying_shares":6476},"source":{"system":"sec-edgar","filing":"0001311210-25-000004","document":"form4-12102025_061234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000131121025000004/form4-12102025_061234.xml","form_type":"4"}},{"id":974235,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:22:38.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":64,"underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001311210-25-000004","document":"form4-12102025_061234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000131121025000004/form4-12102025_061234.xml","form_type":"4"}},{"id":974234,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T18:22:38.000Z","date":"2025-12-09","kind":"other","planned":false,"acquired":false,"shares":8818,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the \"CVR Agreement\") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the \"CVR Agreement\") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001311210-25-000004","document":"form4-12102025_061234.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000131121025000004/form4-12102025_061234.xml","form_type":"4"}},{"id":1077667,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-01T20:05:08.000Z","date":"2025-07-30","kind":"grant","planned":false,"acquired":true,"shares":49800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date."}],"balance_after":49800,"derivative":{"exercise_price":4.1,"expiration_date":"2035-07-29","underlying":"Common Stock","underlying_shares":49800},"source":{"system":"sec-edgar","filing":"0001415889-25-020834","document":"form4-08012025_040803.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588925020834/form4-08012025_040803.xml","form_type":"4"}},{"id":1104785,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:21:51.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":3140,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable on the earlier of June 17, 2026 or the 2026 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":3140,"derivative":{"exercise_price":2.32,"expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":3140},"source":{"system":"sec-edgar","filing":"0001415889-25-017845","document":"form4-06202025_080644.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000141588925017845/form4-06202025_080644.xml","form_type":"4"}},{"id":1104784,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:21:51.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":10450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable on the earlier of June 17, 2026 or the 2026 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":10450,"derivative":{"exercise_price":2.32,"expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":10450},"source":{"system":"sec-edgar","filing":"0001415889-25-017845","document":"form4-06202025_080644.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000141588925017845/form4-06202025_080644.xml","form_type":"4"}},{"id":1113509,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:28:46.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":38300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest in full on the earlier of June 10, 2026 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control."}],"balance_after":38300,"derivative":{"exercise_price":10.02,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":38300},"source":{"system":"sec-edgar","filing":"0001724521-25-000090","document":"wk-form4_1749760118.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000090/wk-form4_1749760118.xml","form_type":"4"}},{"id":1113508,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-12T20:28:46.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":13300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest in full on the earlier of June 10, 2026 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control."}],"balance_after":38600,"source":{"system":"sec-edgar","filing":"0001724521-25-000090","document":"wk-form4_1749760118.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000090/wk-form4_1749760118.xml","form_type":"4"}},{"id":1119332,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2025-06-06T22:00:13.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":2645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":2645,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":2645},"source":{"system":"sec-edgar","filing":"0000950170-25-083328","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000095017025083328/ownership.xml","form_type":"4"}},{"id":1119331,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-06-06T22:00:13.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":17012,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders."}],"balance_after":17012,"derivative":{"exercise_price":30.73,"expiration_date":"2035-06-04","underlying":"Common Shares","underlying_shares":17012},"source":{"system":"sec-edgar","filing":"0000950170-25-083328","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000095017025083328/ownership.xml","form_type":"4"}},{"id":1134933,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-23T20:06:50.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40567,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"1/48 of the shares subject to the option vested on May 19, 2021 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":0,"derivative":{"exercise_price":0.7683,"expiration_date":"2031-07-25","underlying":"Common Stock","underlying_shares":40567},"source":{"system":"sec-edgar","filing":"0001962918-25-000056","document":"wk-form4_1748030799.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000196291825000056/wk-form4_1748030799.xml","form_type":"4"}},{"id":1134932,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-23T20:06:50.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":86206,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"1/48 of the shares subject to the option vested on November 1, 2022 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":0,"derivative":{"exercise_price":5.8766,"expiration_date":"2032-11-20","underlying":"Common Stock","underlying_shares":86206},"source":{"system":"sec-edgar","filing":"0001962918-25-000056","document":"wk-form4_1748030799.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000196291825000056/wk-form4_1748030799.xml","form_type":"4"}},{"id":1134931,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-23T20:06:50.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28675,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/48 of the shares subject to the option vested on December 17, 2022 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":0,"derivative":{"exercise_price":5.8766,"expiration_date":"2032-11-20","underlying":"Common Stock","underlying_shares":28675},"source":{"system":"sec-edgar","filing":"0001962918-25-000056","document":"wk-form4_1748030799.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000196291825000056/wk-form4_1748030799.xml","form_type":"4"}},{"id":1134930,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-23T20:06:50.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23243,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":0,"derivative":{"exercise_price":18,"expiration_date":"2033-05-03","underlying":"Common Stock","underlying_shares":23243},"source":{"system":"sec-edgar","filing":"0001962918-25-000056","document":"wk-form4_1748030799.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000196291825000056/wk-form4_1748030799.xml","form_type":"4"}},{"id":1134929,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-23T20:06:50.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":92158,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":0,"derivative":{"exercise_price":4.46,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":92158},"source":{"system":"sec-edgar","filing":"0001962918-25-000056","document":"wk-form4_1748030799.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000196291825000056/wk-form4_1748030799.xml","form_type":"4"}},{"id":1134928,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T20:06:50.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14675,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the \"Merger Agreement\") with Alumis, Inc., a Delaware corporation (\"Parent\"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the \"Merger\"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the \"Exchange Ratio\") shares of voting common stock of Parent, par value $0.0001 per share (\"Parent Common Stock\"), and cash in lieu of any fractional shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Patrick Machado Revocable Trust, Patrick Machado, TEE, for which the Reporting Person serves as trustee."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001962918-25-000056","document":"wk-form4_1748030799.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000196291825000056/wk-form4_1748030799.xml","form_type":"4"}},{"id":1135524,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-23T20:05:20.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":19528,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F9","text":"Received in the Merger in exchange for an employee stock option to acquire 40,567 shares of ACELYRIN common stock for $0.7683 per share."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Issuer and converted into an option to purchase a number of shares of Issuer Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding ACELYRIN stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 6, 2025, the Issuer entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the \"Merger Agreement\") with ACELYRIN, Inc., a Delaware corporation (\"ACELYRIN\"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into ACELYRIN (the \"Merger\"), with ACELYRIN surviving as a wholly owned subsidiary of Issuer. At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $0.00001 per share, of ACELYRIN issued and outstanding was converted into the right to receive 0.4814 (the \"Exchange Ratio\") shares of voting common stock of Issuer, par value $0.0001 per share, and cash in lieu of any fractional shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Stock Option is fully vested and exercisable."}],"balance_after":19528,"derivative":{"exercise_price":1.6,"expiration_date":"2031-07-25","underlying":"Class A Common Stock","underlying_shares":19528},"source":{"system":"sec-edgar","filing":"0001415889-25-014422","document":"form4-05232025_040512.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588925014422/form4-05232025_040512.xml","form_type":"4"}},{"id":1135523,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-23T20:05:20.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":13804,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F8","text":"Received in the Merger in exchange for an employee stock option to acquire 28,675 shares of ACELYRIN common stock for $5.8766 per share."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Issuer and converted into an option to purchase a number of shares of Issuer Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding ACELYRIN stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 6, 2025, the Issuer entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the \"Merger Agreement\") with ACELYRIN, Inc., a Delaware corporation (\"ACELYRIN\"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into ACELYRIN (the \"Merger\"), with ACELYRIN surviving as a wholly owned subsidiary of Issuer. At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $0.00001 per share, of ACELYRIN issued and outstanding was converted into the right to receive 0.4814 (the \"Exchange Ratio\") shares of voting common stock of Issuer, par value $0.0001 per share, and cash in lieu of any fractional shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Stock Option is fully vested and exercisable."}],"balance_after":13804,"derivative":{"exercise_price":12.21,"expiration_date":"2032-11-20","underlying":"Class A Common Stock","underlying_shares":13804},"source":{"system":"sec-edgar","filing":"0001415889-25-014422","document":"form4-05232025_040512.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588925014422/form4-05232025_040512.xml","form_type":"4"}},{"id":1135522,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-23T20:05:20.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":41499,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F7","text":"Received in the Merger in exchange for an employee stock option to acquire 86,206 shares of ACELYRIN common stock for $5.8766 per share."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Issuer and converted into an option to purchase a number of shares of Issuer Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding ACELYRIN stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 6, 2025, the Issuer entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the \"Merger Agreement\") with ACELYRIN, Inc., a Delaware corporation (\"ACELYRIN\"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into ACELYRIN (the \"Merger\"), with ACELYRIN surviving as a wholly owned subsidiary of Issuer. At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $0.00001 per share, of ACELYRIN issued and outstanding was converted into the right to receive 0.4814 (the \"Exchange Ratio\") shares of voting common stock of Issuer, par value $0.0001 per share, and cash in lieu of any fractional shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Stock Option is fully vested and exercisable."}],"balance_after":41499,"derivative":{"exercise_price":12.21,"expiration_date":"2032-11-20","underlying":"Class A Common Stock","underlying_shares":41499},"source":{"system":"sec-edgar","filing":"0001415889-25-014422","document":"form4-05232025_040512.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588925014422/form4-05232025_040512.xml","form_type":"4"}},{"id":1135521,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-23T20:05:20.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":11189,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F6","text":"Received in the Merger in exchange for an employee stock option to acquire 23,243 shares of ACELYRIN common stock for $18.00 per share."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Issuer and converted into an option to purchase a number of shares of Issuer Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding ACELYRIN stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 6, 2025, the Issuer entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the \"Merger Agreement\") with ACELYRIN, Inc., a Delaware corporation (\"ACELYRIN\"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into ACELYRIN (the \"Merger\"), with ACELYRIN surviving as a wholly owned subsidiary of Issuer. At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $0.00001 per share, of ACELYRIN issued and outstanding was converted into the right to receive 0.4814 (the \"Exchange Ratio\") shares of voting common stock of Issuer, par value $0.0001 per share, and cash in lieu of any fractional shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Stock Option is fully vested and exercisable."}],"balance_after":11189,"derivative":{"exercise_price":37.39,"expiration_date":"2033-05-03","underlying":"Class A Common Stock","underlying_shares":11189},"source":{"system":"sec-edgar","filing":"0001415889-25-014422","document":"form4-05232025_040512.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588925014422/form4-05232025_040512.xml","form_type":"4"}},{"id":1135520,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-23T20:05:20.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":44364,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Received in the Merger in exchange for an employee stock option to acquire 92,158 shares of ACELYRIN common stock for $4.46 per share."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Issuer and converted into an option to purchase a number of shares of Issuer Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding ACELYRIN stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 6, 2025, the Issuer entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the \"Merger Agreement\") with ACELYRIN, Inc., a Delaware corporation (\"ACELYRIN\"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into ACELYRIN (the \"Merger\"), with ACELYRIN surviving as a wholly owned subsidiary of Issuer. At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $0.00001 per share, of ACELYRIN issued and outstanding was converted into the right to receive 0.4814 (the \"Exchange Ratio\") shares of voting common stock of Issuer, par value $0.0001 per share, and cash in lieu of any fractional shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Stock Option is fully vested and exercisable."}],"balance_after":44364,"derivative":{"exercise_price":9.26,"expiration_date":"2034-06-06","underlying":"Class A Common Stock","underlying_shares":44364},"source":{"system":"sec-edgar","filing":"0001415889-25-014422","document":"form4-05232025_040512.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588925014422/form4-05232025_040512.xml","form_type":"4"}},{"id":1135519,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T20:05:20.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":7064,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 6, 2025, the Issuer entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the \"Merger Agreement\") with ACELYRIN, Inc., a Delaware corporation (\"ACELYRIN\"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into ACELYRIN (the \"Merger\"), with ACELYRIN surviving as a wholly owned subsidiary of Issuer. At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $0.00001 per share, of ACELYRIN issued and outstanding was converted into the right to receive 0.4814 (the \"Exchange Ratio\") shares of voting common stock of Issuer, par value $0.0001 per share, and cash in lieu of any fractional shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Patrick Machado Revocable Trust, Patrick Machado, TEE, for which the Reporting Person serves as trustee."}],"balance_after":7064,"source":{"system":"sec-edgar","filing":"0001415889-25-014422","document":"form4-05232025_040512.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588925014422/form4-05232025_040512.xml","form_type":"4"}},{"id":1465981,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:41:36.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests over a 3-year period, with 1/3 of the total number of shares subject to the option vesting on each of the first three anniversaries of June 21, 2024, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":38000,"derivative":{"exercise_price":16,"expiration_date":"2034-06-26","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001415889-24-018604","document":"form4-07012024_080733.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018604/form4-07012024_080733.xml","form_type":"4"}},{"id":1465980,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:41:36.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests over a 3-year period, with 1/3 of the total number of shares subject to the option vesting on each of the first three anniversaries of June 21, 2024, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2034-06-26","underlying":"Class A Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001415889-24-018604","document":"form4-07012024_080733.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018604/form4-07012024_080733.xml","form_type":"4"}},{"id":1465979,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:41:36.000Z","date":"2024-06-27","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests over a 3-year period, with 1/3 of the total number of shares subject to the option vesting on each of the first three anniversaries of June 21, 2024, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":38000,"derivative":{"exercise_price":16,"expiration_date":"2034-06-26","underlying":"Class A Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001415889-24-018604","document":"form4-07012024_080733.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018604/form4-07012024_080733.xml","form_type":"4"}},{"id":1472918,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-20T20:43:59.000Z","date":"2024-06-17","kind":"grant","planned":false,"acquired":true,"shares":3300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable on the earlier of June 17, 2025 or the 2025 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":3300,"derivative":{"exercise_price":7.32,"expiration_date":"2034-06-16","underlying":"Common Stock","underlying_shares":3300},"source":{"system":"sec-edgar","filing":"0001415889-24-017672","document":"form4-06202024_080655.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000141588924017672/form4-06202024_080655.xml","form_type":"4"}},{"id":1472917,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-20T20:43:59.000Z","date":"2024-06-17","kind":"grant","planned":false,"acquired":true,"shares":10520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable on the earlier of June 17, 2025 or the 2025 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":10520,"derivative":{"exercise_price":7.32,"expiration_date":"2034-06-16","underlying":"Common Stock","underlying_shares":10520},"source":{"system":"sec-edgar","filing":"0001415889-24-017672","document":"form4-06202024_080655.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000141588924017672/form4-06202024_080655.xml","form_type":"4"}},{"id":1483160,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2024-06-11T23:09:57.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":92158,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":92158,"derivative":{"exercise_price":4.46,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":92158},"source":{"system":"sec-edgar","filing":"0001962918-24-000089","document":"wk-form4_1718147390.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000196291824000089/wk-form4_1718147390.xml","form_type":"4"}},{"id":1486873,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T22:20:31.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest in full on the earlier of June 6, 2025 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control."}],"balance_after":24000,"derivative":{"exercise_price":15.9,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001724521-24-000113","document":"wk-form4_1717798823.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000113/wk-form4_1717798823.xml","form_type":"4"}},{"id":1486872,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T22:20:31.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":8400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest in full on the earlier of June 6, 2025 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control."}],"balance_after":25300,"source":{"system":"sec-edgar","filing":"0001724521-24-000113","document":"wk-form4_1717798823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000113/wk-form4_1717798823.xml","form_type":"4"}},{"id":1489665,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-05T21:42:53.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":15542,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 100% on the earlier of (i) June 4, 2025 or (ii) the day before the date of the issuer's 2025 annual meeting of shareholders."}],"balance_after":15542,"derivative":{"exercise_price":38.16,"expiration_date":"2034-06-04","underlying":"Common Shares","underlying_shares":15542},"source":{"system":"sec-edgar","filing":"0000950170-24-069467","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000095017024069467/ownership.xml","form_type":"4"}},{"id":1763401,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-06T21:56:09.000Z","date":"2023-10-04","kind":"other","planned":false,"acquired":true,"shares":14675,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata, in-kind distribution, and not a purchase or sale of securities, from Woodland Hills Partner LLC (the \"LLC\") to the Reporting Person, a limited partner of the LLC, without additional consideration. This distribution arises from the purchase of preferred stock by the Reporting Person as a limited partner in the LLC on the same pricing terms as the other participating investors in each round of financing."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Patrick Machado Revocable Trust, Patrick Machado, TEE, for which the Reporting Person serves as trustee."}],"balance_after":14675,"source":{"system":"sec-edgar","filing":"0001962918-23-000037","document":"wk-form4_1696629358.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000196291823000037/wk-form4_1696629358.xml","form_type":"4"}},{"id":1852379,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-17T00:05:13.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest in full on the earlier of June 15, 2024 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control."}],"balance_after":19500,"derivative":{"exercise_price":19.6,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0001209191-23-038142","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919123038142/doc4.xml","form_type":"4"}},{"id":1852378,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-17T00:05:13.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":6800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest in full on the earlier of June 15, 2024 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control."}],"balance_after":16900,"source":{"system":"sec-edgar","filing":"0001209191-23-038142","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919123038142/doc4.xml","form_type":"4"}},{"id":1857003,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-13T21:02:24.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 9, 2024 or the 2024 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":52500,"derivative":{"exercise_price":1.56,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-23-036801","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919123036801/doc4.xml","form_type":"4"}},{"id":1857002,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-13T21:02:24.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 9, 2024 or the 2024 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.56,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-23-036801","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919123036801/doc4.xml","form_type":"4"}},{"id":1859281,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-12T16:28:17.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2024 annual stockholder meeting."}],"balance_after":60000,"derivative":{"exercise_price":1.39,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-23-036319","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919123036319/doc4.xml","form_type":"4"}},{"id":1869262,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-02T21:20:41.000Z","date":"2023-06-02","kind":"grant","planned":false,"acquired":true,"shares":18475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 100% on the earlier of (i) June 1, 2024 or (ii) the day immediately preceding the day of the following year's annual meeting."}],"balance_after":18475,"derivative":{"exercise_price":38.96,"expiration_date":"2033-06-01","underlying":"Common Shares","underlying_shares":18475},"source":{"system":"sec-edgar","filing":"0000950170-23-026167","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000095017023026167/ownership.xml","form_type":"4"}},{"id":1896503,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2023-05-12T01:09:04.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":true,"shares":23243,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock."}],"balance_after":23243,"derivative":{"exercise_price":18,"expiration_date":"2033-05-03","underlying":"Common Stock","underlying_shares":23243},"source":{"system":"sec-edgar","filing":"0001209191-23-028880","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919123028880/doc4.xml","form_type":"4"}},{"id":1896502,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2023-05-12T01:09:04.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":false,"shares":23243,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock."}],"balance_after":0,"derivative":{"exercise_price":18,"expiration_date":"2033-05-03","underlying":"Class A Common Stock","underlying_shares":23243},"source":{"system":"sec-edgar","filing":"0001209191-23-028880","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919123028880/doc4.xml","form_type":"4"}},{"id":1896501,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2023-05-12T01:09:04.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":true,"shares":28675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48 of the shares subject to the option vested on December 17, 2022 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock."}],"balance_after":28675,"derivative":{"exercise_price":5.8766,"expiration_date":"2032-11-20","underlying":"Common Stock","underlying_shares":28675},"source":{"system":"sec-edgar","filing":"0001209191-23-028880","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919123028880/doc4.xml","form_type":"4"}},{"id":1896500,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2023-05-12T01:09:04.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":false,"shares":28675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48 of the shares subject to the option vested on December 17, 2022 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock."}],"balance_after":0,"derivative":{"exercise_price":5.8766,"expiration_date":"2032-11-20","underlying":"Class A Common Stock","underlying_shares":28675},"source":{"system":"sec-edgar","filing":"0001209191-23-028880","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919123028880/doc4.xml","form_type":"4"}},{"id":1896499,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2023-05-12T01:09:04.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":true,"shares":86206,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48 of the shares subject to the option vested on November 1, 2022 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":86206,"derivative":{"exercise_price":5.8766,"expiration_date":"2032-11-20","underlying":"Common Stock","underlying_shares":86206},"source":{"system":"sec-edgar","filing":"0001209191-23-028880","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919123028880/doc4.xml","form_type":"4"}},{"id":1896498,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2023-05-12T01:09:04.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":false,"shares":86206,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48 of the shares subject to the option vested on November 1, 2022 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":0,"derivative":{"exercise_price":5.8766,"expiration_date":"2032-11-20","underlying":"Class A Common Stock","underlying_shares":86206},"source":{"system":"sec-edgar","filing":"0001209191-23-028880","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919123028880/doc4.xml","form_type":"4"}},{"id":1896497,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2023-05-12T01:09:04.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":true,"shares":40567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48 of the shares subject to the option vested on May 19, 2021 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":40567,"derivative":{"exercise_price":0.7683,"expiration_date":"2031-07-25","underlying":"Common Stock","underlying_shares":40567},"source":{"system":"sec-edgar","filing":"0001209191-23-028880","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919123028880/doc4.xml","form_type":"4"}},{"id":1896496,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2023-05-12T01:09:04.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":false,"shares":40567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48 of the shares subject to the option vested on May 19, 2021 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":0,"derivative":{"exercise_price":0.7683,"expiration_date":"2031-07-25","underlying":"Class A Common Stock","underlying_shares":40567},"source":{"system":"sec-edgar","filing":"0001209191-23-028880","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919123028880/doc4.xml","form_type":"4"}},{"id":1904161,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2023-05-05T00:16:49.000Z","date":"2023-05-04","kind":"grant","planned":false,"acquired":true,"shares":23243,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each share of Class A Common Stock shall be reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock."}],"balance_after":23243,"derivative":{"exercise_price":18,"expiration_date":"2033-05-03","underlying":"Class A Common","underlying_shares":23243},"source":{"system":"sec-edgar","filing":"0001209191-23-027534","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919123027534/doc4.xml","form_type":"4"}},{"id":2181156,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-08-17T20:41:51.000Z","date":"2022-08-17","kind":"disposition_to_issuer","acquired":false,"shares":8500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the \"Issuer\"), Bristol-Myers Squibb Company (\"BMS\") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS (\"Purchaser\"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."}],"balance_after":0,"derivative":{"exercise_price":65.64,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001209191-22-046286","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919122046286/doc4.xml","form_type":"4"}},{"id":2181155,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-08-17T20:41:51.000Z","date":"2022-08-17","kind":"disposition_to_issuer","acquired":false,"shares":8500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the \"Issuer\"), Bristol-Myers Squibb Company (\"BMS\") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS (\"Purchaser\"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."}],"balance_after":0,"derivative":{"exercise_price":65.39,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001209191-22-046286","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919122046286/doc4.xml","form_type":"4"}},{"id":2181154,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-08-17T20:41:51.000Z","date":"2022-08-17","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the \"Issuer\"), Bristol-Myers Squibb Company (\"BMS\") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS (\"Purchaser\"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."}],"balance_after":0,"derivative":{"exercise_price":29.56,"expiration_date":"2029-05-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-22-046286","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919122046286/doc4.xml","form_type":"4"}},{"id":2219293,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-29T21:34:56.000Z","date":"2022-06-28","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the common shares subject to the option will vest on the earlier of (i) the first anniversary of grant date and (ii) the day immediately preceding the day of the Issuer's next annual general meeting of shareholders."}],"balance_after":18000,"derivative":{"exercise_price":30.11,"expiration_date":"2032-06-27","underlying":"Common Shares","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-22-039831","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919122039831/doc4.xml","form_type":"4"}},{"id":2222264,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-24T11:10:25.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2023 annual stockholder meeting."}],"balance_after":50000,"derivative":{"exercise_price":1.82,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-22-039117","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919122039117/doc4.xml","form_type":"4"}},{"id":2230009,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-16T20:26:38.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":16800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option will vest in full on the earlier of June 14, 2023 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control."}],"balance_after":16800,"derivative":{"exercise_price":20.62,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":16800},"source":{"system":"sec-edgar","filing":"0001209191-22-037417","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919122037417/doc4.xml","form_type":"4"}},{"id":2230008,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-16T20:26:38.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":4100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest in full on the earlier of June 14, 2023 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,000 shares of restricted stock units (previously reported) that vested on June 3, 2022."}],"balance_after":10100,"source":{"system":"sec-edgar","filing":"0001209191-22-037417","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919122037417/doc4.xml","form_type":"4"}},{"id":2232383,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-14T20:19:31.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 10, 2023 or the 2023 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":12500,"derivative":{"exercise_price":0.9903,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-22-036675","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919122036675/doc4.xml","form_type":"4"}},{"id":2232382,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-14T20:19:31.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 10, 2023 or the 2023 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":40000,"derivative":{"exercise_price":0.9903,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-22-036675","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919122036675/doc4.xml","form_type":"4"}},{"id":2655069,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-25T17:24:13.000Z","date":"2021-06-23","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2022 annual stockholder meeting."}],"balance_after":35000,"derivative":{"exercise_price":7.84,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-21-043350","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919121043350/doc4.xml","form_type":"4"}},{"id":2679417,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-07T20:40:41.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":14100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control."}],"balance_after":14100,"derivative":{"exercise_price":24.79,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":14100},"source":{"system":"sec-edgar","filing":"0001209191-21-038628","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919121038628/doc4.xml","form_type":"4"}},{"id":2679416,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-07T20:40:41.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest 100% on the earlier of June 3, 2022 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,000 shares of restricted stock units (previously reported) that vested on June 3, 2021."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001209191-21-038628","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919121038628/doc4.xml","form_type":"4"}},{"id":2680605,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-04T21:41:28.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the one-year anniversary of the date of grant."}],"balance_after":8500,"derivative":{"exercise_price":65.64,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001209191-21-038334","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919121038334/doc4.xml","form_type":"4"}},{"id":2682701,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T01:09:40.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to\nthe Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year\nanniversary of the grant date."}],"balance_after":10000,"derivative":{"exercise_price":18.56,"expiration_date":"2031-06-02","underlying":"Common Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-038070","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919121038070/doc4.xml","form_type":"4"}},{"id":2712021,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-15T00:01:13.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of May 12, 2022 or the 2022 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":12500,"derivative":{"exercise_price":3.7,"expiration_date":"2031-05-11","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-21-032953","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919121032953/doc4.xml","form_type":"4"}},{"id":2712020,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-15T00:01:13.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of May 12, 2022 or the 2022 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":40000,"derivative":{"exercise_price":3.7,"expiration_date":"2031-05-11","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-032953","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919121032953/doc4.xml","form_type":"4"}},{"id":2772965,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-24T23:46:53.000Z","date":"2021-03-24","kind":"purchase","acquired":true,"shares":10000,"price":9.9196,"value":99196.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $9.76 to $10.045. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":88182,"source":{"system":"sec-edgar","filing":"0001209191-21-022933","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919121022933/doc4.xml","form_type":"4"}},{"id":2904028,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-20T01:33:27.000Z","date":"2021-01-15","kind":"purchase","acquired":true,"shares":10000,"price":11.5174,"value":115174.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $11.495 to $11.52. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":78182,"source":{"system":"sec-edgar","filing":"0001209191-21-004143","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919121004143/doc4.xml","form_type":"4"}},{"id":2990885,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-06T00:14:32.000Z","date":"2020-11-05","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date."}],"balance_after":20000,"derivative":{"exercise_price":11.85,"expiration_date":"2030-11-04","underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-20-057208","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919120057208/doc4.xml","form_type":"4"}},{"id":3021599,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-09-28T21:28:51.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":10240,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":62.66,"expiration_date":"2030-06-03","underlying":"Common Stock","underlying_shares":10240},"source":{"system":"sec-edgar","filing":"0001209191-20-052235","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919120052235/doc4.xml","form_type":"4"}},{"id":3021598,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-09-28T21:28:51.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":10240,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":31.77,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":10240},"source":{"system":"sec-edgar","filing":"0001209191-20-052235","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919120052235/doc4.xml","form_type":"4"}},{"id":3021597,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-09-28T21:28:51.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":20475,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":31.77,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":20475},"source":{"system":"sec-edgar","filing":"0001209191-20-052235","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919120052235/doc4.xml","form_type":"4"}},{"id":3099631,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-25T21:46:38.000Z","date":"2020-06-23","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 23, 2021 or the 2021 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":30000,"derivative":{"exercise_price":25.64,"expiration_date":"2030-06-22","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-20-038962","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919120038962/doc4.xml","form_type":"4"}},{"id":3106602,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-17T23:06:31.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the one-year anniversary of the date of grant."}],"balance_after":8500,"derivative":{"exercise_price":65.39,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001209191-20-037415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919120037415/doc4.xml","form_type":"4"}},{"id":3110824,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-15T12:43:21.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2020 annual stockholder meeting."}],"balance_after":35000,"derivative":{"exercise_price":2.85,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-20-036526","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919120036526/doc4.xml","form_type":"4"}},{"id":3118306,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-06-09T00:10:34.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":10240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":10240,"derivative":{"exercise_price":62.66,"expiration_date":"2030-06-03","underlying":"Common Stock","underlying_shares":10240},"source":{"system":"sec-edgar","filing":"0001209191-20-035143","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919120035143/doc4.xml","form_type":"4"}},{"id":3118856,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-08T20:32:43.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control."}],"balance_after":14000,"derivative":{"exercise_price":30.05,"expiration_date":"2030-06-03","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001209191-20-034986","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919120034986/doc4.xml","form_type":"4"}},{"id":3118855,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-08T20:32:43.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest 100% on the earlier of June 4, 2021 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control"}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001209191-20-034986","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919120034986/doc4.xml","form_type":"4"}},{"id":3322063,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-03T21:34:02.000Z","date":"2020-01-01","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier to occur of 18 months following January 1, 2020 or the 2021 annual meeting of stockholders."}],"balance_after":15000,"derivative":{"exercise_price":11.52,"expiration_date":"2029-12-31","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-001014","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919120001014/doc4.xml","form_type":"4"}},{"id":3343777,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-12-12T17:18:06.000Z","date":"2019-12-10","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is exercisable in 36 equal monthly installments after December 10, 2019, subject to the Reporting Person's continued service to the Company."}],"balance_after":50000,"derivative":{"exercise_price":8.55,"expiration_date":"2029-12-09","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-19-060168","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919119060168/doc4.xml","form_type":"4"}},{"id":3448852,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-08-02T20:27:46.000Z","date":"2019-07-31","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of (a) the 2020 annual meeting of stockholders and (b) July 31, 2020."}],"balance_after":45000,"derivative":{"exercise_price":13.41,"expiration_date":"2029-07-30","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-19-044260","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000120919119044260/doc4.xml","form_type":"4"}},{"id":3480335,"issuer":{"id":80651,"kind":"organization","name":"CHIMERIX INC","symbol":"CMRX"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-24T14:37:42.000Z","date":"2019-06-20","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2020 annual stockholder meeting."}],"balance_after":21000,"derivative":{"exercise_price":3.37,"expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001209191-19-038725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1117480/000120919119038725/doc4.xml","form_type":"4"}},{"id":3483922,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-19T22:30:28.000Z","date":"2019-06-19","kind":"purchase","acquired":true,"shares":4957,"price":8.1693,"value":40495.2201,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the reporting person. See footnotes 3 and 4 for information on the reporting person's ownership via Roivant of the purchased Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.00 to $8.27, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the reporting person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person was appointed as an Independent Director of Roivant effective October 18, 2016."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22860013,"source":{"system":"sec-edgar","filing":"0001104659-19-036422","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000110465919036422/a4.xml","form_type":"4"}},{"id":3483921,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-19T22:30:28.000Z","date":"2019-06-18","kind":"purchase","acquired":true,"shares":6706,"price":8.2107,"value":55060.9542,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the reporting person. See footnotes 3 and 4 for information on the reporting person's ownership via Roivant of the purchased Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.09 to $8.29, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the reporting person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person was appointed as an Independent Director of Roivant effective October 18, 2016."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22855056,"source":{"system":"sec-edgar","filing":"0001104659-19-036422","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000110465919036422/a4.xml","form_type":"4"}},{"id":3483920,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":32934,"kind":"person","name":"Machado Patrick","position":1,"cik":"0001311210","reported_name":"Machado Patrick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-19T22:30:28.000Z","date":"2019-06-17","kind":"purchase","acquired":true,"shares":6541,"price":8.5346,"value":55824.8186,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the reporting person. See footnotes 3 and 4 for information on the reporting person's ownership via Roivant of the purchased Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.11 to $8.70, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. (\"Urovant\"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the reporting person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person was appointed as an Independent Director of Roivant effective October 18, 2016."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22848350,"source":{"system":"sec-edgar","filing":"0001104659-19-036422","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311210/000110465919036422/a4.xml","form_type":"4"}}],"next_cursor":"2019-06-19T22:30:28.000000Z,3483920"}